TimothyRGershonMD
Child Neurology • Atlanta, GAActing Professor of Pediatrics Director, Children’s Center for Neurosciences Research Emory University School of Medicine
Dr. Gershon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
ECC 256
https://sites.google.com/view/timothygershonlabemory/home
Atlanta, GA 30322Phone+1 404-785-5437
Summary
- I am a board certified Neurologist with Special Qualification in Child Neurology. I also run a research lab that studies microcephaly and pediatric brain tumors as disorders of brain growth. To learn more, please visit:
https://sites.google.com/view/timothygershonlabemory/home
I completed fellowship training in Neuro-oncology at Memorial Sloan Kettering Cancer Center. My areas of expertise are medulloblastoma and neurofibromatosis, and the use of targeted inhibitors to treat neurologic disease.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Child Neurology, 2001 - 2004- New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 1999 - 2001
Columbia University Vagelos College of Physicians and SurgeonsClass of 1999
Certifications & Licensure
GA State Medical License 2022 - 2026
NC State Medical License 2009 - 2023
NY State Medical License 2001 - 2011
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
Clinical Trials
- PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Start of enrollment: 2013 Jan 16
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Publications & Presentations
PubMed
- 2 citationsReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20 - 1 citationsSuppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179.Yuchen Li, Chaemin Lim, Taylor Dismuke, Daniel S Malawsky, Sho Oasa
Nature Communications. 2025-02-04 - 2 citationsChronic AMPK inactivation slows SHH medulloblastoma progression by inhibiting mTORC1 signaling and depleting tumor stem cells.Daniel Shiloh Malawsky, Taylor Dismuke, Hedi Liu, Ethan Castellino, Jay Brenman
Iscience. 2023-12-15
Press Mentions
New Drug, CT-179, Holds Promise for Treating MedulloblastomaFebruary 4th, 2025- Experimental Medulloblastoma Treatment Gets a Boost with NanoparticlesFebruary 25th, 2022
- Case Reports Underscore Risk of Cerebral Edema, AFCE in Children with COVID-19October 7th, 2021
- Join now to see all
External Links
- Lab Websitehttps://sites.google.com/view/timothygershonlabemory/home
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
